Clinical study using mesenchymal stem cells for the treatment of patients with severe COVID-19
- PDF / 306,444 Bytes
- 10 Pages / 595.276 x 785.197 pts Page_size
- 91 Downloads / 176 Views
LETTER TO FRONTIERS OF MEDICINE
Clinical study using mesenchymal stem cells for the treatment of patients with severe COVID-19 Lingling Tang1,*, Yingan Jiang2,*, Mengfei Zhu1,*, Lijun Chen3,*, Xiaoyang Zhou2, Chenliang Zhou2, Peng Ye2, Xiaobei Chen2, Baohong Wang3, Zhenyu Xu4, Qiang Zhang4, Xiaowei Xu3, Hainv Gao1, Xiaojun Wu2, Dong Li2,
Wanli Jiang2, Jingjing Qu3, Charlie Xiang (✉)3, Lanjuan Li (✉)1,3
1 The Shulan (Hangzhou) Hospital, Affiliated to Shulan International Medical College, Zhejiang Shuren University, Hangzhou 310022, China; 2Department of Infectious Diseases, Renmin Hospital of Wuhan University, Wuhan 430060, China; 3State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou 310003, China; 4Innovative Precision Medicine (IPM) Group, Hangzhou 311215, China
© Higher Education Press 2020
Abstract The coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2 was identified in December 2019. The symptoms include fever, cough, dyspnea, early symptom of sputum, and acute respiratory distress syndrome (ARDS). Mesenchymal stem cell (MSC) therapy is the immediate treatment used for patients with severe cases of COVID-19. Herein, we describe two confirmed cases of COVID-19 in Wuhan to explore the role of MSC in the treatment of COVID-19. MSC transplantation increases the immune indicators (including CD4 and lymphocytes) and decreases the inflammation indicators (interleukin-6 and C-reactive protein). High-flow nasal cannula can be used as an initial support strategy for patients with ARDS. With MSC transplantation, the fraction of inspired O2 (FiO2) of the two patients gradually decreased while the oxygen saturation (SaO2) and partial pressure of oxygen (PO2) improved. Additionally, the patients’ chest computed tomography showed that bilateral lung exudate lesions were adsorbed after MSC infusion. Results indicated that MSC transplantation provides clinical data on the treatment of COVID-19 and may serve as an alternative method for treating COVID-19, particularly in patients with ARDS. Keywords coronavirus disease 2019 (COVID-19); mesenchymal stem cell; acute respiratory distress syndrome; stem cell therapeutics
Introduction The coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2 was identified in December 2019 [1–3] and is regarded as a highly infectious epidemic disease [4–6]. As of June 6, 2020, the Chinese National Health Commission reported 84 624 confirmed cases and over 4645 deaths. Current epidemiological investigations show that the exposure of many patients can be traced to live seafood and wildlife markets [7,8]. Therefore, the host of SARS-CoV-2 could be a wild animal, such as bats,
Received April 26, 2020; accepted June 10, 2020 Correspondence: Charlie Xiang, [email protected]; Lanjuan Li, [email protected] *
Lingling Tang, Yingan Jiang, Mengfei Zhu, and Lijun C
Data Loading...
